Evidence map›Paper›PMID 31192908›Full record

Trial reportMedicine2019

Efficacy and safety of sustained-release oxycodone compared with immediate-release morphine for pain titration in cancer patients: A multicenter, open-label, randomized controlled trial (SOCIAL).

Hongming Pan, Peng Shen, Qijin Shu, Liqin Lu, Suying Qian, Yuefen Zhou, Feng Han, Qunyi Guo, Zhiping Yang, Jie Pan and 3 more

Open access · goldAbstract readComparative StudyMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Oxycodone for cancer-related pain.The Cochrane database of systematic reviews · 2022
    Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 10 institutions in 1 country.

Hongming PanDepartment of Medical Oncology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Zhejiang.
Peng ShenDepartment of Medical Oncology, The First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang.
Qijin ShuDepartment of Medical Oncology, Zhejiang Provincial Hospital of Traditional Chinese Medicine, Hangzhou, Zhejiang.
Liqin LuDepartment of Medical Oncology, The People's Hospital of Zhejiang Province, Hangzhou, Zhejiang.
Suying QianDepartment of Medical Oncology, The Second People's Hospital of Ningbo City, Zhejiang, Ningbo.
Yuefen ZhouDepartment of Medical Oncology, Lishui Central Hospital, Lishui, Zhejiang.
Feng HanDepartment of Medical Oncology, Shangyu People's Hospital, Shaoxing, Zhejiang.
Qunyi GuoDepartment of Medical Oncology, Taizhou Hospital of Zhejiang Province, Taizhou, Zhejiang.
Zhiping YangDepartment of Medical Oncology, The First People's Hospital of Jiaxing City, Jiaxing, Zhejiang.
Jie PanDepartment of Medical Oncology, People's Hospital of Lin'an City, Lin'an, Zhejiang.
Qing XuDepartment of Medical Oncology, Shanghai Tenth People's Hospital, Shanghai.
Peng ZhangSchool of Mathematical Sciences, Zhejiang University.
Kaifeng WangDepartment of Medical Oncology, Hangzhou Cancer Hospital, Hangzhou, China.
First Affiliated Hospital Zhejiang University · CNFirst Hospital of Jiaxing · CNHangzhou Cancer Hospital · CNLishui Central Hospital · CNShanghai Tenth People's Hospital · CNSir Run Run Shaw Hospital · CNXian Yang Central Hospital · CNZhejiang Provincial Hospital of TCM · CNZhejiang Taizhou Hospital · CNZhejiang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe study aims to investigate the effect and safety of sustained-release oxycodone hydrochloride as background dose on pain titration in patients with moderate-to-severe cancer pain. MATERIAL AND

methodsAdult patients scheduled with a regular strong opioid for cancer-related pain were recruited and randomly assigned to sustained-release oxycodone group (tablets, 12 hourly) and immediate-release morphine group (5 mg initially, hourly). All patients were hourly reassessed for efficacy and dose titration.

resultsThe primary end point was the number of titration cycles required to achieve adequate pain relief (numerical rating scale, NRS ≤ 3). Secondary end points included the proportion of patients achieving adequate pain relief during each cycle, potential predictive factors for titration performance, and side effects. Ninety (94.7%) patients in oxycodone group and 78 (86.7%) patients in morphine group achieved adequate pain control during 1 to 4 cycles of titration. Patients in oxycodone group reached adequate pain control within the first 2 cycles of titration, which was significantly shorter than morphine group wherein the number of titration cycles ranged from 1 to 4 (P = .034). Oxycodone prescription significantly increased the response rate of patients to morphine titration during the first cycle of titration (P = .010). The initial NRS score and oxycodone administration were significantly associated with titration performance. The mild or moderate adverse effects were similar in 2 groups, while severe adverse effects were only identified in morphine group (P = .001).

conclusionUse of background sustained-release oxycodone is more efficient and better tolerated on dose titration than immediate-release morphine.

Indexed as

AgedCancer PainDelayed-Action PreparationsFemaleHumansMaleMiddle AgedMorphineOxycodonePain MeasurementTreatment OutcomeDelayed-Action PreparationsMorphineOxycodone

Identifiers

PMID31192908
PMCPMC6587615
OpenAlexW2952637955

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.